Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a prominent player in the life science research and clinical diagnostics markets, is scheduled to report its financial results for the third quarter of 2025 on Wednesday, October 29, 2025. The announcement will be made after the market closes, followed by a conference call to discuss the results at 2:00 PM Pacific Time (5:00 PM Eastern Time). Stakeholders wishing to participate can call (800) 715-9871 from within the U.S. or (646) 307-1963 from outside the U.S., using access code 9562470.

For those unable to join the call, a live webcast along with a supplemental earnings presentation will be accessible in the "Investor Relations" section of the company’s website under "Events & Presentations". A replay of the webcast will be available for viewing for up to a year post the live event.

Founded in Hercules, California, Bio-Rad operates a robust global network dedicated to the research, development, manufacturing, and marketing of scientific products and services. With approximately 7,500 employees and reported revenues of around $2.6 billion in 2024, Bio-Rad serves a diverse customer base that includes universities, hospitals, biopharmaceutical companies, and laboratories focused on clinical diagnostics, food safety, and environmental quality.

As Bio-Rad prepares to share its financial performance, market analysts and investors will be keenly awaiting insights into the company's growth trajectory, strategic initiatives, and innovations that continue to enhance scientific advancement and health outcomes. For further information, interested parties can visit bio-rad.com or contact Investor Relations representative Edward Chung at 510-741-6104 or via email at ir@bio-rad.com.

As Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) approaches its third-quarter financial results announcement on October 29, 2025, investors should exercise critical analysis of the company’s performance and market positioning. With $2.6 billion in revenues in 2024, Bio-Rad remains a key player in the life science research and clinical diagnostics markets. Anticipation surrounding the earnings report is fueled by the continual demand for innovative biotechnology solutions, especially in research, clinical diagnostics, and environmental testing.

Analysts will closely scrutinize Bio-Rad's revenue growth, gross margins, and expense management during the recent quarter. Look for insights into their product performance—especially any advancements in high-demand diagnostics or lab products that could influence revenue trajectories. The ongoing trends in personalized medicine, genomics, and rapid testing solutions remain critical drivers, and any disclosures regarding new product launches, collaborations, or market expansions could significantly impact investor sentiment.

Moreover, investor attention is likely to focus on Bio-Rad's guidance for the rest of the fiscal year. The company’s management will, during the conference call at 2:00 PM PT, provide insights that will assist in delineating future growth prospects. Robust earnings might prompt upward revisions of earnings forecasts, while weaker-than-expected results may signal the need for caution amidst competitive pressures and economic uncertainties.

Technically, investors should watch for the stock's reaction post-announcement. Key resistance levels will reveal potential upward momentum, whereas a breach of support could indicate bearish trends. Given Bio-Rad’s historical performance and its robust market fundamentals, prudent investors may consider positioning themselves for either a tactical entry based on earnings momentum or a strategic hold should the results align with long-term growth perspectives. Always align your investment strategies with comprehensive risk assessments.